Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
3 Top Genomics Stocks to Add to Your Portfolio in 2025
10:05am, Wednesday, 21'st May 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
08:00am, Monday, 19'th May 2025
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rache
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?
11:00am, Wednesday, 14'th May 2025
The consensus price target hints at a 161.5% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript
10:16pm, Friday, 09'th May 2025
uniQure N.V. (NASDAQ:QURE ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director, Investor Relations Matt Kapusta - Chief Executive Officer Walid
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
09:20am, Friday, 09'th May 2025
UniQure (QURE) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.36 per share a year ago.
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
07:05am, Friday, 09'th May 2025
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
05:16am, Thursday, 08'th May 2025
uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phas
uniQure to Announce First Quarter 2025 Financial Results
04:05pm, Monday, 05'th May 2025
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ ~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
10:55am, Monday, 21'st Apr 2025
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
01:56am, Monday, 21'st Apr 2025
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volat
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
08:31am, Saturday, 19'th Apr 2025
uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operat
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?
10:27am, Thursday, 17'th Apr 2025
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.'s QURE AMT-130 for Huntington's disease on Thursday
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease
07:17am, Thursday, 17'th Apr 2025
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
09:35am, Thursday, 27'th Feb 2025
UniQure (QURE) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.53 per share a year ago.
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
07:05am, Thursday, 27'th Feb 2025
~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential B
